Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results
BridgeBio Pharma showcased impressive revenue growth throughout 2025, fueled by surging sales of its flagship ATTR-CM treatment Attruby, alongside strategic financial maneuvers that bolstered its cash position and supported pipeline advancements, prompting widespread analyst optimism with consensus buy ratings and elevated price targets averaging around $85, reflecting confidence in sustained momentum and multi-product potential. BridgeBio … Read more